Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis

A Phase 2, multicenter, double-blind, placebo control study evaluating the safety and efficacy of Thykamine in adult patient suffering of mild-to-moderate Atopic Dermatitis

Study Overview

• Status: Completed
• Conditions: Atopic Dermatitis Eczema
• Intervention / Treatment: Drug: Administration of Placebo; Drug: Administration of PUR0110 (Thykamine) 0.05%; Drug: Administration of PUR0110 (Thykamine) 0.1%; Drug: Administration of PUR0110 (Thykamine) 0.25%

Detailed Description

4-week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of Three Concentrations (0.05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis.

• Study Type: Interventional
• Enrollment (Actual): 162
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Québec, Canada, G1V 4X7
    • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
  • Ontario
    • Barrie, Ontario, Canada, L4M 7G1
      • SimcoDerm Medical and Surgical Dermatology Center
    • Burlington, Ontario, Canada, L7M 4Y1
      • Manna Research Inc. (Burlington North)
    • London, Ontario, Canada, N6H 5L5
      • Dermeffects
    • Markham, Ontario, Canada, L3P 1X2
      • Lynderm Research Inc.
    • Toronto, Ontario, Canada, M9W 4L6
      • Manna Research Inc. (Toronto)
    • Windsor, Ontario, Canada, N8W5L7
      • Windsor Clinical Research Inc.
  • Ontation
    • Mississauga, Ontation, Canada, L5H 1G9
      • DermEdge Research imc.
  • Quebec
    • Chicoutimi, Quebec, Canada, G7H 7Y8
      • Q&T Research Chicoutimi
    • Drummondville, Quebec, Canada, J2B 5L4
      • Dr. Isabelle Delorme Inc.
    • Montréal, Quebec, Canada, H3H 1V4
      • Dr. David Gratton Dermatologue Inc.
    • Québec, Quebec, Canada, G1W 4R4
      • Centre de Recherche Saint-Louis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria

The patient must meet all the following criteria to be enrolled in the study:

1. Male or female patients, aged 18 years or older at the screening visit.
2. Patients with diagnosis of AD for at least 6 months prior to Day 0 visit as defined by the criteria of Hanifin and Rajka (Acta Derm Venereol. 1980).
3. Patients with BSA ≥ 1 % and ≤ 15% at Day 0 (excluding palms, soles and scalp).
4. Patients with IGA score of 2 to 3 (mild-to-moderate) at Day 0.
5. Female patients of childbearing potential must have a negative pregnancy test (serum Beta-hCG) at the screening visit - unless they are surgically sterile (hysterectomy, bilateral oophorectomy or tubal ligation), in a menopausal state for at least a year, clinically diagnosed infertile, or have a same-sex partner or are abstinent.

6. In addition, females of childbearing potential or a male patient with a female partner must be willing to use an effective contraceptive method for at least 30 days (12 weeks for hormonal contraceptives) before Day 0 and at least 1 month after the last study drug administration. Effective contraceptive methods include:

   • Barrier methods such as condom, sponge or diaphragm combined with spermicide in foam, gel or cream;
   • Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo Provera, Evra and Nuvaring; and
   • Intrauterine device (IUD).
7. Patients must be capable of giving informed consent and the consent must be obtained prior to any study related procedures.

Exclusion criteria

1. Patient with BSA > 15% (excluding palms, soles and scalp).
2. Female who is pregnant or lactating or wishes to become pregnant during the study period.
3. Patient with a history of any confounding inflammatory skin diseases or any other skin disease, e.g., psoriasis, rosacea, erythroderma or ichthyosis, that could impair his/her safety during the study or interfere with the evaluation of AD.
4. Patient with spontaneously improving or rapidly deteriorating AD.
5. Patient with active allergic contact dermatitis or other non-atopic forms of dermatitis.
6. Patient with active cutaneous bacterial or viral or fungal infection in any treatment area at baseline (e.g., clinically infected AD).
7. Patient with acute infections.
8. Patient with a history or presence of Netherton's syndrome, immunological deficiencies or diseases, diabetes, malignancy, psychological disorders, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders - which might cause this study to be detrimental to the patient or that may confound the study results or interfere significantly with the patient's participation in the study.
9. Patient with bleeding disorders.
10. Patient with known seropositivity for the human immunodeficiency virus or evidence of active hepatitis B or C.
11. Patient has an unstable or serious medical condition, as defined by the investigator, which might cause this study to be detrimental to the patient or that may confound the study results or interfere significantly with the patient's participation in the study.
12. Patient has a history of alcoholism or drug abuse within 12 months prior to Day 0.
13. Patient with known allergy, or history of allergic reaction, or hypersensitivity to spinach, spinach tablet, spinach powder or spinach extract; to mushrooms; or any ingredients present in PUR 0110.
14. Patient with a history of severe food allergies.
15. Patient with sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at baseline (Day 0), which would interfere with evaluations.
16. Use within 4 weeks prior to baseline (Day 0) of oral or intravenous corticosteroids, UVA/UVB therapy, PUVA (psoralen plus ultraviolet A) therapy, tanning booths, non-prescription UV light sources, immunomodulators or immunosuppressive therapies, interferon, or cytotoxic drugs.
17. Use within 2 weeks of baseline (Day 0) of systemic antibiotics, calcipotriene or other vitamin D preparations, or retinoids.
18. Use within 2 weeks of baseline (Day 0) of oral natural health products or vitamins containing lutein.
19. Use within 1 week prior to baseline (Day 0) of antihistamines, topical antibiotics, topical corticosteroids, topical calcineurin inhibitors or other topical drug products used for treating AD. Inhaled corticosteroids for stable medical conditions are allowed.
20. Use within 24 hours prior to baseline (Day 0) of any topical product (e.g., sunscreens, lotions, creams) in the areas to be treated, except for bland emollient (moisturizer).
21. Use of an investigational agent within 4 weeks or 5 half-lives prior to Day 0 (whichever is longer).
22. Patient not willing to minimize or avoid natural and artificial sunlight exposure during treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Administration of Placebo	Drug: Administration of Placebo; Botanical Drug Phase 2 clinical study; Other Names: Placebo control
Experimental: PUR0110 (Thykamine) 0.05%; Administration of PUR0110 (Thykamine) 0.05%	Drug: Administration of PUR0110 (Thykamine) 0.05%; Botanical Drug Phase 2 clinical study; Other Names: Active arm
Experimental: PUR0110 (Thykamine) 0.10%; Administration of PUR0110 (Thykamine) 0.10%	Drug: Administration of PUR0110 (Thykamine) 0.1%; Botanical Drug Phase 2 clinical study; Other Names: Active arm
Experimental: PUR0110 (Thykamine) 0.25%; Administration of PUR0110 (Thykamine) 0.25%	Drug: Administration of PUR0110 (Thykamine) 0.25%; Botanical Drug Phase 2 clinical study; Other Names: Active arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy as per investigator global assessment (IGA)	Efficacy as per investigator global assessment (IGA) of clear (0), almost clear (1) at Day 29 and with a decrease from baseline in IGA of at least 2 grades at Day 29.	Baseline and 4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of adverse events (AEs) (systemic and local)	Incidence and severity of adverse events (AEs) (systemic and local) as a measure of safety and tolerability of treatment for up to Day 29.	Baseline and 4 weeks
Change from baseline in Atopic Dermatitis (AD) score	Change from baseline to Day 29 in the 4 individual signs/symptoms score of AD including: erythema, induration/papulation, excoriation and lichenification measured in the target lesion on a 4-point scale defined as : 0 = None; 1=Mild; 2=Moderate and 3=Severe	Baseline and 4 weeks
Change in pruritus	Change from baseline to Day 29 in pruritus, measured on a 4-point scale defined as : 0=None; 1=Mild; 2=Moderate and 3=Severe	Baseline and 4 weeks
Proportion of patients with change in Investigator Global Assessment (IGA)	• Proportion of patients with an IGA of clear (0), almost clear (1) and with a decrease from baseline in IGA of at least 2 grades at intermediate visits (Days 7, 14 and 21). Scores being defined as : 0=Clear ; 1=Almost Clear; 2:=Mild disease; 3=Moderate disease and 4 = Severe disease	Baseline and 3 weeks
Change in Eczema Area and Severity Index (EASI)	Change from baseline to Day 29 in Eczema Area and Severity Index (EASI).Four body regions are considered separately and include: Head and neck; Trunk ; Upper extremities; Lower extremities (including the buttocks).Extent of Eczema in these regions is being scored as follow : 0 = 0% involvement; 1= 1-9%; 2 = 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89% and 6= 90-100%. Severity of erythema, edema/papulation, excoriation and lichenification , for each region is scaled as : 0=none; 1= mild; 2= moderate and 3= severe. Final EASI score is the sum of the 4 region scores and ranges from 0-72.	Baseline and 4 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
EASI improvement	Proportion of patients with at least a 50% and 75% improvement in EASI (EASI50) at Day 29 as compared to baseline	Baseline and 4 weeks
Change from baseline in body surface area (BSA).	Change from baseline to Day 29 in body surface area (BSA) affected by disease.	Baseline and 4 weeks
Change from baseline in Dermatology Life Quality Index (DLQI).	Change from baseline to Day 29 in Dermatology Life Quality Index (DLQI) evaluating the impact on Quality of life scale : Very much ; A lot; a little or Not at all.	Baseline and 4 weeks
Change from baseline in Patient-Oriented Eczema Measure (POEM).	Change from baseline to Day 29 in Patient-Oriented Eczema Measure (POEM) investigating the number of days patients have been subjected, due to eczema, to itchy skin, sleep disturbance; skin bleeding; skin weeping; skin craked; skin flaking and skin dryness. Scale defined as : 0 = no days; 1= 1-2 days; 2= 3-4 days; 3= 5-6 days; 4 = everyday	Baseline and 4 weeks

Collaborators and Investigators

• Sponsor: PurGenesis Technologies Inc.
• Investigators: Study Director: Yves Poulin, MD, Centre de Recherche Dernatologique du Quebec; Study Director: Wei Jing Loo, MD, Dermeffects

Study record dates

Study Major Dates

• Study Start (Actual): October 23, 2017
• Primary Completion (Actual): December 31, 2019
• Study Completion (Actual): June 3, 2020

Study Registration Dates

• First Submitted: April 15, 2018
• First Submitted That Met QC Criteria: May 25, 2018
• First Posted (Actual): May 30, 2018

Study Record Updates

• Last Update Posted (Actual): September 16, 2021
• Last Update Submitted That Met QC Criteria: September 15, 2021
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: Mild moderate atopic dermatitis
• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Eczema; Dermatitis, Atopic
• Other Study ID Numbers: DV16-PUR0110-C001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No